

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

**Date of Report:** May 10, 2017  
**Commission File Number:** 001-36891

**Collectis S.A.**  
**(Exact Name of registrant as specified in its charter)**

**8, rue de la Croix Jarry  
75013 Paris, France  
+33 1 81 69 16 00  
(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

**EXHIBIT INDEX**

<b><u>Exhibit</u></b>	<b><u>Title</u></b>
99.1	Press release, dated May 10, 2017

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CELLECTIS S.A.**

(Registrant)

May 10, 2017

By: /s/ André Choulika

\_\_\_\_\_  
André Choulika

Chief Executive Officer

**Calyxt Patent Encompassing Broad Uses of Plant Gene Editing Technologies Maintained by USPTO*****U.S. Patent 8,921,332 Refers to the Use of Chimeric Endonucleases, such as Zinc Finger Nucleases, TAL-effector Nucleases, Mega-TALs and CRISPR/Cas9 to Precisely Edit DNA within Plant Genomes***

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--May 10, 2017--Calyxt, Inc., a Minnesota-based company developing healthier food products to benefit both consumers and farmers, today announced that U.S. patent 8,921,332, which claims the use of chimeric restriction endonucleases for directing chromosomal gene editing in cells by homologous recombination (HR), initially issued on Dec. 30, 2014, has been upheld by the United States Patent and Trademark Office (USPTO) after a reexamination initiated in October 2015.

U.S. patent 8,921,332 claims a general method for modifying chromosomal DNA sequences at a genomic site of interest within a cell by using chimeric restriction endonucleases, such as zinc finger nucleases, TAL-effector nucleases, Mega-TALs and CRISPR/Cas9. This technique, commonly referred to as gene targeting or targeted insertion, is now frequently used to modify the genome within plants, animals and cell lines.

The inventors of this patent are Dr. André Choulika, Collectis CEO, and Dr. Richard Mulligan, a Harvard Medical School Professor. Institut Pasteur and Boston Children's Hospital, the owners of the patent, have granted exclusive rights under this patent to Collectis, Calyxt's parent company. It belongs to a patent family that claims the basic uses of chimeric restriction nucleases for gene editing in cells.

Following the patent's reexamination, the USPTO issued a Notice to Issue Reexamination Certificate in which it is stated that all 55 claims of the patent are maintained, asserting that, "*The '632 patent, Smith et al., the '150 patent, Kim et al. and the '261 patent individually or in combination neither teach or suggest the method of modifying a specific sequence in a chromosomal DNA of a cell in vitro by contacting the cell with a chimeric restriction endonuclease and a targeted DNA as recited in the present claims.*"

---

## About Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. By combining its leading gene-editing technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier food ingredients for consumers and agriculturally advantageous traits for farmers. Calyxt is developing or creating specialty food ingredients, such as healthier oils and high fiber wheat, and food crops with desirable traits such as herbicide tolerance. Calyxt is located in Minneapolis-St. Paul, Minn., and is a wholly owned subsidiary of Collectis.

For further information please visit our website: [www.calyxt.com](http://www.calyxt.com)  
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.

Talking about gene editing? We do it.

TALEN® is a registered trademark owned by the Collectis Group.

### CONTACT:

#### **For Calyxt**

#### **Media:**

Jennifer Moore, 917-580-1088

VP Communications

[contact@calyxt.com](mailto:contact@calyxt.com)

or

KCSA Strategic Communications

Caitlin Kasunich / Nick Opich

212-896-1241 / 212-896-1206

[ckasunich@kcsa.com](mailto:ckasunich@kcsa.com) / [nopich@kcsa.com](mailto:nopich@kcsa.com)

or

#### **Investor Relations:**

Simon Harnest, 646-385-9008

VP Corporate Strategy and Finance

[simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)